Antifungal therapy in European hospitals: Data from the ESAC point-prevalence surveys 2008 and 2009

P. Zarb, B. Amadeo, A. Muller, N. Drapier, V. Vankerckhoven, P. Davey, H. Goossens, Sigrid Metz-Gercek, Hilde Jansens, Boyka Markova, Christiana Kontemeniotou, Arjana Andrasevic, Jiri Vlcek, Niels Frimodt-Møller, Piret Mitt, Outi Lyytikainen, Xavier Bertrand, Katja de With, Anastasia Antoniadou, Gabor TernakRobert Cunney, Raul Raz, Silvio Brusaferro, Elina Dimina, Vitalija Butkyte, Bruch Marcel, Jon Birger Haug, Janina Pawlowksa, Ines Teixeira, Svetlana Ratchina, Milan Cizman, Mercedes Sora, Gunilla Skoog, Giorgio Zanetti, Margreet Filius, Yesim Cetinkaya Sardan, Jonathan Cooke, Hugh Webb, Margaret Heginbothom

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The study aimed to identify targets for quality improvement in antifungal use in European hospitals and determine the variability of such prescribing. Hospitals that participated in the European Surveillance of Antimicrobial Consumption Point Prevalence Surveys (ESAC-PPS) were included. The WHO Anatomical Therapeutic Chemical (ATC) classification for 'antimycotics for systemic use' (J02) 2009 version was used. Demographic data and information about indications and diagnoses were collected in 2008 and 2009. From 99053 patients, 29324 (29.6%) received antimicrobials. Antifungals represented 1529 of 40878 (3.7%) antimicrobials. Antifungals were mainly (54.2%) administered orally. Hospital-acquired infections represented 44.5% of indications for antifungals followed by medical prophylaxis at 31.2%. The site of infection was not defined in 36.0% of cases but the most commonly targeted sites were respiratory (19.2%) and gastrointestinal (18.8%). The most used antifungal was fluconazole (60.5%) followed by caspofungin (10.5%). Antifungal-antibacterial combinations were frequently used (77.5%). The predominance of fluconazole use in participating hospitals could result in an increase in prevalence of inherently resistant fungi, increasing the need for newer antifungals. Although acknowledging that antifungal prophylaxis in the immunocompromised host needs further exploration, repetitive surveys using ESAC-PPS methodology may help to monitor the effects of interventions set to regulate antifungal use.

Original languageEnglish
Pages (from-to)E389-E395
JournalClinical Microbiology and Infection
Volume18
Issue number10
DOIs
Publication statusPublished - Oct 2012

Keywords

  • Fluconazole
  • Hospital antifungal consumption
  • Hospital-acquired infections
  • Medical prophylaxis
  • Point-prevalence surveys

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Antifungal therapy in European hospitals: Data from the ESAC point-prevalence surveys 2008 and 2009'. Together they form a unique fingerprint.

  • Cite this

    Zarb, P., Amadeo, B., Muller, A., Drapier, N., Vankerckhoven, V., Davey, P., Goossens, H., Metz-Gercek, S., Jansens, H., Markova, B., Kontemeniotou, C., Andrasevic, A., Vlcek, J., Frimodt-Møller, N., Mitt, P., Lyytikainen, O., Bertrand, X., de With, K., Antoniadou, A., ... Heginbothom, M. (2012). Antifungal therapy in European hospitals: Data from the ESAC point-prevalence surveys 2008 and 2009. Clinical Microbiology and Infection, 18(10), E389-E395. https://doi.org/10.1111/j.1469-0691.2012.03973.x